SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.

From July 28th through August 2nd, SCCM will be performing maintenance on its websites. Users may experience intermittent issues when trying to access online courses, assessments and director-led portals for online courses.

SARI-PREP

Severe Acute Respiratory Infection - Preparedness (SARI-PREP) aims to rapidly inform and improve clinical management of epidemic/pandemic SARI patients.

visual bubble
visual bubble
visual bubble
visual bubble
SARI-PREP is a multicenter consortium funded by the CDC Foundation. It is being assembled with the goal of providing the infrastructure to rapidly collect prospective data on clinical risks and outcomes, hospital-level stress, and biologic specimens that will aid in the rapid development of diagnostic and treatment approaches.
 
Specific causes of severe acute respiratory infection (SARI) to be targeted by SARI-PREP include SARS-CoV-2, influenza A and B viruses, and other known or novel viral infections causing outbreaks, epidemics, and pandemics of SARI.
 
The information gained will help to rapidly inform and improve clinical management of epidemic/pandemic SARI patients. The completion date is March 2022. The National Clinical Trial number is NCT04786301.
 

What are the study objectives?

  • Identify the clinical characteristics and treatments associated with risk for severity of disease and important clinical outcomes in hospitalized patients at high-risk for SARI due to respiratory viral illness caused by pathogens such as SARS-CoV-2 and influenza A and B viruses
  • Identify clinical characteristics and treatments differentiating patients with SARI due to specific respiratory viruses such as SARS-CoV-2 and influenza A among hospitalized patients with suspected viral SARI
  • Identify the molecular markers of risk for poor in-hospital and post-discharge clinical outcomes in hospitalized patients with viral SARI
  • Evaluate which patient characteristics and treatments are associated with organ failure-free days and mortality in patients with viral SARI
  • Report the natural history of a large cohort of patients with confirmed viral SARI
visual bubble
visual bubble
visual bubble
visual bubble
visual bubble

What are the inclusion and exclusion criteria?

Inclusion criteria:
  1. At-risk cohort requires admission to an acute care or intensive care unit with a clinical syndrome of lower respiratory tract infection suspicious for viral SARI. This will be defined by the presence of fever, cough, and radiographic infiltrates by imaging (chest radiograph, CT, etc.) or Spo2 ≤ 94% on room air or requiring new supplemental oxygen (above baseline if preexisting) or requiring invasive or noninvasive mechanical ventilation.
  2. Case cohort requires the above criteria plus confirmed viral cause for SARI by respiratory viral reverse transcription polymerase chain reaction testing.
 
Exclusion criteria:
  • Prisoners or wards of the state
  • Inability to consent or lack of availability of legal surrogate
  • Status of do-not-attempt resuscitation or do-not-intubate on admission

SARI-PREP Investigators

University of Washington, University of Nebraska, Emory University, and Discovery, the Critical Care Research Network, are leading the consortium study.
Laura E. Evans, MD
Principal Investigator
Laura E. Evans, MD

Co-Investigators:
  • George Anesi, MD, MSCE, MBE (University of Pennsylvania)
  • Pavan Bhatraju, MD, MSc (University of Washington)
  • J. Perren Cobb, MD, FCCM (University of Southern California)
  • Chris Kratochvil, MD (University of Nebraska)
  • Doug Landsittel, PhD (University of Pittsburgh)
  • Richard Lee, MD (University of California, Irvine)
  • Janice Lieber, MD (University of Southern California)
  • Karen Lutrick, PhD (University of Arizona)
  • David Brett-Major, MD, MPH (University of Nebraska)
  • Vikramjit Mukherjee, MD (NYU Langone)
  • Radu Postelnicu, MD (NYU Langone)
  • Leopoldo N. Segal, MD (NYU Langone)
  • Jonathan E. Sevransky, MD, FCCM (Emory University)
  • Timothy Uyeki, MD (Centers for Disease Control and Prevention)
  • Mark M. Wurfel, MD, PhD (University of Washington)
  • David Wyles, MD (Denver Health)
Institutional Review Board
Central institutional review board (IRB) will be through the University of Nebraska. For additional IRB information, please contact SCCM staff.

Society of Critical Care Medicine Contacts: Adair Andrews RN, MATD and Vishakha Kumar, MD, MBA